カテゴリー： 世界, MarketsandMarkets

リキッドバイオプシーの世界市場（～2030年）

【英語タイトル】Liquid Biopsy Market by Product & Service (Kits, Instruments), Circulating Biomarker (ctDNA, cfDNA, CTC), Technology (NGS, PCR), Application (Lung, Breast, Prostate Cancer), Sample Type (Blood, Urine, CSF), End User (Hospitals) - Global Forecast to 2030

MarketsandMarketsが出版した調査資料（MD 4456）・商品コード：MD 4456
・発行会社（調査会社）：MarketsandMarkets
・発行日：2025年7月
・ページ数：380
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後1営業日）
・調査対象地域：グローバル
・産業分野：バイオ
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD4,950 ⇒換算￥712,800見積依頼/購入/質問フォーム
Corporate License（法人閲覧用）USD8,150 ⇒換算￥1,173,600見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

リキッドバイオプシー市場は、2024年に約36.5億米ドル、2025年に約40.3億米ドルに達し、2025年から2030年にかけて年平均成長率（CAGR）11.8％で拡大し、2030年には約70.5億米ドルに達すると予測されている。成長の主因は、世界的な癌の罹患率増加と早期・正確な疾病検出への需要の高まりである。リキッドバイオプシーは、腫瘍のリアルタイムモニタリングや治療耐性の追跡を可能にし、標的治療を行う医師に重要な情報を提供する。また、非侵襲的出生前診断や移植医療などの分野でも応用が広がっている。次世代シーケンシング（NGS）やバイオマーカー検出技術の進歩により、感度や信頼性が向上し、さらに精密医療への投資拡大と非侵襲的診断需要の増大が市場拡大を後押ししている。

地域別では、北米が2024年に最大シェアを占めており、先進的な医療インフラや研究開発力、精密腫瘍学への高い認知が寄与している。一方、アジア太平洋地域は今後最も高い成長が見込まれており、癌患者数の増加、医療インフラ整備、診断技術への投資拡大、早期検出意識の高まりが背景にある。市場の拡大要因には、従来の組織生検の限界や、精密腫瘍学におけるリキッドバイオプシー採用の増加、規制当局の支援などがある。企業戦略としては、提携や製品承認が主要な成長手段となっている。

一方で課題も存在する。感度・特異度の低さにより一部検査で循環腫瘍DNA（ctDNA）が検出されず、偽陰性を生むリスクがあることが挙げられる。また、保険償還の不透明さが普及の妨げとなっており、高額な分子診断検査の費用負担が患者や医療機関にとって大きな課題となっている。特に多遺伝子パネル検査が一部の保険者で限定的にしかカバーされないことは臨床的有用性を制限している。

市場機会としては、コンパニオン診断の重要性の高まりがある。リキッドバイオプシーは非侵襲的に作用可能なバイオマーカーを検出できるため、特定の治療から最も恩恵を受ける患者層を特定するのに適しており、製薬企業と診断企業の協業が進んでいる。市場構造としては、リファレンスラボ、病院、医師ラボ、学術・研究機関などが主要なエンドユーザーであり、循環バイオマーカーの種類ではctDNAセグメントが最も高成長が予測される。ctDNAは腫瘍遺伝子の変化をリアルタイムで把握でき、早期診断や治療モニタリング、耐性変異の検出に強みを持つため、精密医療での利用が拡大している。検体別では血液検体が主流であり、利便性や安全性、費用対効果の高さ、幅広い臨床実証に基づき今後も支配的地位を維持する。

近年の動向としては、Natera社が2025年に超高感度のSignatera Genome-MRD検査を米国で発売し、Myriad Genetics社は乳癌リスク評価の遠隔医療サービスを提供するGabbi社と提携、またIntermountain Healthの一部資産を取得するなど活発な動きが見られる。主な市場参加企業にはNatera、QIAGEN、Illumina、ロシュ、Thermo Fisher Scientific、Guardant Health、Exact Sciences、Sysmexなどが含まれる。これら企業は技術革新や提携を通じて市場拡大を推進しており、リキッドバイオプシーは今後、腫瘍学を中心とした個別化医療の中核技術として一層重要性を増していくとみられる。

The global liquid biopsy market, valued at US$3.65 billion in 2024, stood at US$4.03 billion in 2025 and is projected to advance at a resilient CAGR of 11.8% from 2025 to 2030, culminating in a forecasted valuation of US$7.05 billion by the end of the period. The increasing global cancer incidence and the growing emphasis on early and precise disease detection primarily drive this market expansion. Liquid biopsy techniques enable real-time tumor monitoring and facilitate the tracking of resistance development to specific therapies, thereby providing crucial insights for physicians utilizing targeted cancer treatments. Furthermore, these tests are gaining traction in non-invasive prenatal testing and transplantation, broadening their clinical utility.

Additionally, technological advancements such as next-generation sequencing (NGS) and improved biomarker detection methods are enhancing the sensitivity and reliability of liquid biopsy tests. Furthermore, rising investments from both public and private sectors in precision medicine, coupled with a growing demand for early and non-invasive diagnostic solutions, are further propelling the adoption of liquid biopsy across various healthcare settings.

The growing incidence of cancer is a primary factor driving the growth of the liquid biopsy market. As cancer cases continue to rise, there is increasing demand for diagnostic methods that can detect the disease at earlier stages, monitor progression, and guide treatment decisions. Liquid biopsy offers a non-invasive, repeatable alternative to traditional tissue biopsies, making it particularly valuable in oncology care. Being minimally invasive, liquid biopsy enables the detection of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers, making it well-suited for repeated monitoring and early diagnosis. As cancer becomes more prevalent, healthcare systems prioritize technologies that support timely and accurate clinical decision-making, further accelerating the adoption of liquid biopsy products and services.

The key end users of the liquid biopsy market ecosystem are reference laboratories, hospitals, physician laboratories, academic & research centers, and other end users. The market is segmented by circulating biomarkers into circulating tumor cells, tumor DNA, cell-free DNA, extracellular vesicles, and other circulating biomarkers. This ecosystem is further influenced by advancements in liquid biopsy products and regulatory approvals.

KEY PLAYERS IN THE LIQUID BIOPSY MARKET INCLUDE

Natera, Inc. (US)
QIAGEN (Netherlands)
Myriad Genetics, Inc. (US)
Illumina, Inc. (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
Thermo Fisher Scientific Inc. (US)
Guardant Health (US)
Bio-Rad Laboratories, Inc. (US)
Exact Sciences Corporation (US)
Sysmex Corporation (Japan)
maxhealth (US)
Personalis, Inc. (US)
GRAIL, Inc. (US)
Menarini-Silicon Biosystems (Italy)
NeoGenomics. Laboratories (US)
ANGLE plc (UK)
Vortex Biotech Holdings (US)
Bio-Techne (US)
MedGenome (US)
Mesa Labs, Inc. (US)
Labcorp Holdings Inc (US)
Freenome, Holdings, Inc. (US)
Strand (India)
LungLife Al, Inc. (US)
Lucence Health Inc. (US)
New Day Diagnostics, LLC (US)

❖ レポートの目次 ❖

INTRODUCTION
35
RESEARCH METHODOLOGY
40
EXECUTIVE SUMMARY
53
PREMIUM INSIGHTS
59
MARKET OVERVIEW
64
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
     DRIVERS
    – Increasing burden of cancer
    – Cancer awareness initiatives undertaken by global health organizations
    – Expanding benefits of liquid biopsy over traditional biopsy procedures
     RESTRAINTS
    – Lower sensitivity of specific liquid biopsy procedures
     OPPORTUNITIES
    – Growing significance of companion diagnostics
    – Growth potential of emerging economies
     CHALLENGES
    – Unfavorable reimbursement scenario
  • 5.3 PRICING ANALYSIS
     INDICATIVE SELLING PRICE TREND OF LIQUID BIOPSY PRODUCTS, 2023−2025
     INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023−2025
     INDICATIVE SELLING PRICE TREND OF LIQUID BIOPSY PRODUCTS, BY REGION, 2023−2025
  • 5.4 PATENT ANALYSIS
     LIST OF MAJOR PATENTS
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 TRADE ANALYSIS
     TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
     IMPORT DATA (HS CODE 3822)
     EXPORT DATA (HS CODE 3822)
  • 5.8 ECOSYSTEM ANALYSIS
  • 5.9 PORTER’S FIVE FORCES ANALYSIS
     THREAT OF NEW ENTRANTS
     THREAT OF SUBSTITUTES
     BARGAINING POWER OF BUYERS
     BARGAINING POWER OF SUPPLIERS
     INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 REGULATORY LANDSCAPE
     REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
     NORTH AMERICA
    – US
    – Canada
     EUROPE
     ASIA PACIFIC
    – China
    – Japan
    – India
     LATIN AMERICA
    – Brazil
    – Mexico
     MIDDLE EAST
    – Africa
  • 5.11 TECHNOLOGY ANALYSIS
     KEY TECHNOLOGIES
    – Digital Droplet PCR (ddPCR)
    – Tagged-amplicon Deep Sequencing (TAm-Seq)
     COMPLEMENTARY TECHNOLOGIES
    – Electrochemical biosensing technology
     ADJACENT TECHNOLOGIES
    – Microfluidic-based devices
  • 5.12 KEY CONFERENCES & EVENTS, 2025–2026
  • 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
     KEY STAKEHOLDERS IN BUYING PROCESS
     BUYING CRITERIA
  • 5.15 INVESTMENT & FUNDING SCENARIO
  • 5.16 CASE STUDY ANALYSIS
     CASE STUDY 1: DETECTION OF LOW-FREQUENCY MUTATIONS USING TARGET SELECTOR CTDNA TECHNOLOGY
     CASE STUDY 2: ANALYTICAL ASSESSMENT OF PLASMA & SERUM FOR CTDNA MUTATION DETECTION
  • 5.17 IMPACT OF AI/GENERATIVE AI ON LIQUID BIOPSY MARKET
     INTRODUCTION
     MARKET POTENTIAL OF AI
     AI USE CASES
     FUTURE OF AI IN LIQUID BIOPSY MARKET
  • 5.18 TRUMP TARIFF IMPACT ON LIQUID BIOPSY MARKET
     INTRODUCTION
     KEY TARIFF RATES
     PRICE IMPACT ANALYSIS
     KEY IMPACT ON COUNTRY/REGION
    – North America
    – Europe
    – Asia Pacific
     IMPACT ON END-USE INDUSTRIES
    – Reference laboratories
    – Hospitals & physicians’ laboratories
    – Academic & research centers
LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE
100
  • 6.1 INTRODUCTION
  • 6.2 ASSAY KITS
     RECURRING PURCHASE TO PROPEL MARKET
  • 6.3 INSTRUMENTS
     RISING TECHNOLOGICAL ADVANCES IN DDPCR TO FUEL MARKET
  • 6.4 SERVICES
     ADOPTION OF CFDNA & CTC TESTING SERVICES TO SUPPORT MARKET GROWTH
LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE
111
  • 7.1 INTRODUCTION
  • 7.2 CIRCULATING TUMOR DNA
     HIGH SENSITIVITY & SPECIFICITY TO PROPEL MARKET
  • 7.3 CELL-FREE DNA
     BROADENING APPLICATIONS IN PRENATAL SCREENING TO DRIVE MARKET
  • 7.4 CIRCULATING TUMOR CELLS
     EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF TUMORS TO FUEL MARKET
  • 7.5 EXTRACELLULAR VESICLES
     HIGH STABILITY IN BLOOD CIRCULATION TO ENSURE CONSISTENT GROWTH
  • 7.6 OTHER CIRCULATING BIOMARKERS
LIQUID BIOPSY MARKET, BY TECHNOLOGY
128
  • 8.1 INTRODUCTION
  • 8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS
     HIGHER THROUGHPUT EFFICIENCY TO PROPEL MARKET
  • 8.3 SINGLE-GENE ANALYSIS USING PCR MICROARRAYS
     COST-EFFICIENCY AND EASE OF USE TO FUEL UPTAKE
LIQUID BIOPSY MARKET, BY APPLICATION
136
  • 9.1 INTRODUCTION
  • 9.2 CANCER APPLICATIONS
     LUNG CANCER
    – Growing prevalence of lung cancer to propel market
     BREAST CANCER
    – Increasing funding investments for breast cancer research to drive market
     COLORECTAL CANCER
    – Rising geriatric population to fuel uptake
     PROSTATE CANCER
    – Adoption of tumor cell kits to boost demand
     MELANOMA
    – Growing need for early diagnosis of genetically mutated tumors to drive market
     OTHER CANCERS
  • 9.3 NON-CANCER APPLICATIONS
     NON-INVASIVE PRENATAL TESTING
    – Growing demand for NIPT in high-risk pregnancies to drive market
     ORGAN TRANSPLANTATION
    – Early disease diagnosis & detection to support market growth
     INFECTIOUS DISEASE TESTING
    – Potential accuracy & efficacy for testing to fuel uptake
LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION
171
  • 10.1 INTRODUCTION
  • 10.2 THERAPY SELECTION
     GROWING PREFERENCE FOR PERSONALIZED TREATMENT TO DRIVE MARKET
  • 10.3 TREATMENT MONITORING
     EARLY DETECTION OF DISEASE PROGRESSION TO BOOST DEMAND
  • 10.4 EARLY CANCER SCREENING
     GROWING INCIDENCE OF CANCER AND RISING FUNDING INVESTMENTS TO PROPEL MARKET
  • 10.5 RECURRENCE MONITORING
     RISING NEED FOR POST-TREATMENT SURVEILLANCE TO FUEL UPTAKE
LIQUID BIOPSY MARKET, BY SAMPLE TYPE
183
  • 11.1 INTRODUCTION
  • 11.2 BLOOD SAMPLES
     STANDARD SIMPLICITY AND HIGH PATIENT ACCEPTANCE TO PROPEL MARKET
  • 11.3 OTHER SAMPLE TYPES
LIQUID BIOPSY MARKET, BY END USER
191
  • 12.1 INTRODUCTION
  • 12.2 REFERENCE LABORATORIES
     RISING OUTSOURCING OF TESTS AND ABILITY TO UNDERTAKE LARGE SAMPLE VOLUMES TO PROPEL MARKET
  • 12.3 HOSPITALS & PHYSICIANS LABORATORIES
     INCREASING ESTABLISHMENT OF HOSPITALS TO BOOST DEMAND
  • 12.4 ACADEMIC & RESEARCH CENTERS
     INCREASING R&D ACTIVITIES FOR INNOVATIVE TESTS TO SUPPORT MARKET GROWTH
  • 12.5 OTHER END USERS
LIQUID BIOPSY MARKET, BY REGION
204
  • 13.1 INTRODUCTION
  • 13.2 NORTH AMERICA
     NORTH AMERICA: MACROECONOMIC OUTLOOK
     US
    – High healthcare expenditure to propel market
     CANADA
    – Availability of various cancer screening programs to drive market
  • 13.3 EUROPE
     EUROPE: MACROECONOMIC OUTLOOK
     GERMANY
    – Favorable research funding investments for cancer research to fuel market
     UK
    – NHS-funded lab-based disease screening facilities to boost demand
     FRANCE
    – Growing focus on expanding access to advanced genomic technologies to drive market
     ITALY
    – Development of novel circulating cancer biomarkers to support market growth
     SPAIN
    – Focus on personalized medicine to support market uptake
     REST OF EUROPE
  • 13.4 ASIA PACIFIC
     ASIA PACIFIC: MACROECONOMIC OUTLOOK
     CHINA
    – Increasing incidence of infectious diseases to propel market
     JAPAN
    – Universal healthcare reimbursement policy to fuel market
     INDIA
    – Increasing incidence of chronic diseases and growing focus on early disease diagnosis to drive market
     REST OF ASIA PACIFIC
  • 13.5 LATIN AMERICA
     LATIN AMERICA: MACROECONOMIC OUTLOOK
     BRAZIL
    – Improvements in laboratory infrastructure to drive market
     MEXICO
    – Improving accessibility to advanced healthcare services to support market growth
     REST OF LATIN AMERICA
  • 13.6 MIDDLE EAST & AFRICA
     INCREASING COLLABORATIONS & DEVELOPMENTS FOR ENHANCED DIAGNOSTIC ACCESS TO SUPPORT MARKET GROWTH
     MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
COMPETITIVE LANDSCAPE
292
  • 14.1 INTRODUCTION
  • 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
     OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN LIQUID BIOPSY MARKET
  • 14.3 REVENUE ANALYSIS, 2022−2024
  • 14.4 MARKET SHARE ANALYSIS
     LIQUID BIOPSY MARKET
  • 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
     STARS
     EMERGING LEADERS
     PERVASIVE PLAYERS
     PARTICIPANTS
     COMPANY FOOTPRINT: KEY PLAYERS, 2024
    – Company footprint
    – Region footprint
    – Product & Service footprint
  • 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES
     PROGRESSIVE COMPANIES
     RESPONSIVE COMPANIES
     DYNAMIC COMPANIES
     STARTING BLOCKS
     COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    – Detailed list of key startups/SMEs
    – Competitive benchmarking of key startups/SMEs, by product & service
    – Competitive benchmarking of key startups/SMEs, by region
  • 14.7 COMPANY VALUATION & FINANCIAL METRICS
     FINANCIAL METRICS
     COMPANY VALUATION
  • 14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
     BRAND COMPARISON OF PCR-BASED LIQUID BIOPSY ASSAYS
    – QIAGEN N.V.
    – Thermo Fisher Scientific Inc.
    – Bio-Rad Laboratories, Inc.
  • 14.9 COMPETITIVE SCENARIO
     PRODUCT/SERVICE LAUNCHES & APPROVALS
     DEALS
     EXPANSIONS
COMPANY PROFILES
311
  • 15.1 KEY PLAYERS
     NATERA, INC.
    – Business overview
    – Products/Services offered
    – Recent developments
    – MnM view
     GUARDANT HEALTH
    – Business overview
    – Products/Services offered
    – Recent developments
    – MnM view
     MYRIAD GENETICS, INC.
    – Business overview
    – Products/Services offered
    – Recent developments
    – MnM view
     ILLUMINA, INC.
    – Business overview
    – Products/Services offered
    – Recent developments
    – MnM view
     F. HOFFMANN-LA ROCHE LTD.
    – Business overview
    – Products/Services offered
    – Recent developments
    – MnM view
     QIAGEN N.V.
    – Business overview
    – Products/Services offered
    – Recent developments
     EXACT SCIENCES CORPORATION
    – Business overview
    – Products/Services offered
    – Recent developments
     THERMO FISHER SCIENTIFIC INC.
    – Business overview
    – Products/Services offered
    – Recent developments
     GRAIL, INC.
    – Business overview
    – Products/Services offered
    – Recent developments
     BIO-RAD LABORATORIES, INC.
    – Business overview
    – Products/Services offered
    – Recent developments
     SYSMEX CORPORATION
    – Business overview
    – Products/Services offered
    – Recent developments
     MDXHEALTH
    – Business overview
    – Products/Services offered
    – Recent developments
     PERSONALIS, INC.
    – Business overview
    – Products/Services offered
    – Recent developments
     THE MENARINI GROUP
    – Business overview
    – Products/Services offered
    – Recent developments
  • 15.2 OTHER PLAYERS
     NEOGENOMICS LABORATORIES
     ANGLE PLC
     LABCORP HOLDINGS INC.
     BIO-TECHNE
     MESA LABS, INC.
     MEDGENOME
     LUNGLIFE AI, INC.
     STRAND
     VORTEX BIOTECH HOLDINGS
     FREENOME HOLDINGS, INC.
     LUCENCE HEALTH INC.
     NEW DAY DIAGNOSTICS, LLC
LIST OF TABLES
  • TABLE 1 LIQUID BIOPSY MARKET: KEY DATA FROM PRIMARY SOURCES
  • TABLE 2 LIQUID BIOPSY MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 3 INCIDENCE OF CANCER CASES WORLDWIDE, BY TYPE (2022)
  • TABLE 4 PROJECTED INCREASE IN CANCER PATIENTS, 2022 VS. 2035 VS. 2050, BY REGION
  • TABLE 5 INDICATIVE SELLING PRICING TREND OF LIQUID BIOPSY PRODUCTS, 2023–2025
  • TABLE 6 INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023–2025
  • TABLE 7 INDICATIVE SELLING PRICE TREND OF LIQUID BIOPSY PRODUCTS, BY REGION, 2023–2025
  • TABLE 8 LIQUID BIOPSY MARKET: LIST OF KEY PATENTS
  • TABLE 9 IMPORT DATA (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION)
  • TABLE 10 EXPORT DATA (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION)
  • TABLE 11 LIQUID BIOPSY MARKET: ROLE IN THE ECOSYSTEM
  • TABLE 12 LIQUID BIOPSY MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 EUROPE: CLASSIFICATION OF DEVICES
  • TABLE 15 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 16 LIQUID BIOPSY MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026
  • TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS (%)
  • TABLE 18 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS, BY RANK
  • TABLE 19 IMPLEMENTATION OF AI, BY KEY COMPANY & USE CASE
  • TABLE 20 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 21 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 22 KEY ASSAY KITS CURRENTLY OFFERED
  • TABLE 23 LIQUID BIOPSY ASSAY KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 24 NORTH AMERICA: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 25 EUROPE: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 26 ASIA PACIFIC: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 27 LATIN AMERICA: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 28 KEY INSTRUMENTS CURRENTLY OFFERED
  • TABLE 29 LIQUID BIOPSY INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 30 NORTH AMERICA: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 31 EUROPE: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 32 ASIA PACIFIC: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 33 LATIN AMERICA: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 34 LIQUID BIOPSY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 35 NORTH AMERICA: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 36 EUROPE: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 37 ASIA PACIFIC: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 38 LATIN AMERICA: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 39 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 40 KEY CTDNA PRODUCTS CURRENTLY AVAILABLE
  • TABLE 41 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 42 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 43 EUROPE: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 44 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 45 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 46 KEY CELL-FREE DNA PRODUCTS CURRENTLY AVAILABLE
  • TABLE 47 LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 48 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 49 EUROPE: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 50 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 51 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 52 KEY CTC PRODUCTS CURRENTLY AVAILABLE
  • TABLE 53 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 54 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 55 EUROPE: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 56 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 57 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 58 KEY EXTRACELLULAR VESICLE PRODUCTS CURRENTLY AVAILABLE
  • TABLE 59 LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 60 NORTH AMERICA: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 61 EUROPE: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 62 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 63 LATIN AMERICA: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 64 OTHER CIRCULATING BIOMARKER PRODUCTS CURRENTLY AVAILABLE
  • TABLE 65 LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 66 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 67 EUROPE: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 68 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 69 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 70 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 71 KEY NGS-BASED PRODUCTS CURRENTLY AVAILABLE
  • TABLE 72 LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 73 NORTH AMERICA: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 74 EUROPE: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 75 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 76 LATIN AMERICA: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 77 KEY PCR & MICROARRAY-BASED PRODUCTS CURRENTLY AVAILABLE
  • TABLE 78 LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 79 NORTH AMERICA: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 80 EUROPE: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 82 LATIN AMERICA: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 83 LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 84 GLOBAL CANCER INCIDENCE, 2022 VS. 2035 VS. 2045, BY REGION
  • TABLE 85 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 86 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 87 EUROPE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 89 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 90 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 91 GLOBAL LUNG CANCER INCIDENCE, 2022 VS. 2035 VS. 2050
  • TABLE 92 KEY LIQUID BIOPSY PRODUCTS FOR LUNG CANCER
  • TABLE 93 LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 94 NORTH AMERICA: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 95 EUROPE: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 96 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 97 LATIN AMERICA: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 98 GLOBAL BREAST CANCER INCIDENCE, 2022 VS. 2035 VS. 2050
  • TABLE 99 KEY LIQUID BIOPSY PRODUCTS FOR BREAST CANCER
  • TABLE 100 LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 101 NORTH AMERICA: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 102 EUROPE: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 103 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 104 LATIN AMERICA: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 105 GLOBAL COLORECTAL CANCER INCIDENCE, 2022 VS. 2035 VS. 2050
  • TABLE 106 KEY LIQUID BIOPSY PRODUCTS FOR COLORECTAL CANCER
  • TABLE 107 LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 108 NORTH AMERICA: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 109 EUROPE: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 111 LATIN AMERICA: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 112 GLOBAL PROSTATE CANCER INCIDENCE, 2022 VS. 2035 VS. 2050
  • TABLE 113 KEY LIQUID BIOPSY PRODUCTS FOR PROSTATE CANCER
  • TABLE 114 LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 115 NORTH AMERICA: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 116 EUROPE: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 118 LATIN AMERICA: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 119 GLOBAL MELANOMA INCIDENCE, 2022 VS. 2035 VS. 2050
  • TABLE 120 LIQUID BIOPSY MARKET FOR MELANOMA, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 121 NORTH AMERICA: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 122 EUROPE: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 124 LATIN AMERICA: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 125 GLOBAL INCIDENCE OF OTHER CANCERS, 2022 VS. 2050
  • TABLE 126 LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 127 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 128 EUROPE: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 129 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 130 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 131 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 132 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 133 NORTH AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 134 EUROPE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 135 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 136 LATIN AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 137 KEY NIPT LIQUID BIOPSY PRODUCTS
  • TABLE 138 LIQUID BIOPSY MARKET FOR NIPT, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 139 NORTH AMERICA: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 140 EUROPE: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 141 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 142 LATIN AMERICA: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 143 LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 144 NORTH AMERICA: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 145 EUROPE: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 146 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 147 LATIN AMERICA: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 148 LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 149 NORTH AMERICA: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 150 EUROPE: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 151 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 152 LATIN AMERICA: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 153 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 154 LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 155 NORTH AMERICA: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 156 EUROPE: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 157 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 158 LATIN AMERICA: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 159 LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 160 NORTH AMERICA: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 161 EUROPE: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 162 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 163 LATIN AMERICA: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 164 LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 165 NORTH AMERICA: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 166 EUROPE: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 167 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 168 LATIN AMERICA: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 169 LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 170 NORTH AMERICA: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 171 EUROPE: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 172 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 173 LATIN AMERICA: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 174 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 175 LIQUID BIOPSY SAMPLES & APPLICATIONS
  • TABLE 176 KEY BLOOD SAMPLE-BASED PRODUCTS CURRENTLY AVAILABLE
  • TABLE 177 LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY REGION,2023–2030 (USD MILLION)
  • TABLE 178 NORTH AMERICA: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 179 EUROPE: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 180 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 181 LATIN AMERICA: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 182 LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 183 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 184 EUROPE: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 185 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 186 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 187 LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 188 LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 189 NORTH AMERICA: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 190 EUROPE: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 191 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 192 LATIN AMERICA: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 193 LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 194 NORTH AMERICA: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 195 EUROPE: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 196 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 197 LATIN AMERICA: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 198 LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 199 NORTH AMERICA: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 200 EUROPE: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 201 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 202 LATIN AMERICA: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 203 LIQUID BIOPSY MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 204 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 205 EUROPE: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 206 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 207 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 208 LIQUID BIOPSY MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 209 NORTH AMERICA: NUMBER OF NEW CANCER CASES, BY CANCER TYPE, 2022 VS. 2050
  • TABLE 210 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 211 NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 212 NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 213 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 214 NORTH AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 215 NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 216 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 217 NORTH AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 218 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 219 NORTH AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 220 NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 221 US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 222 US: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 223 US: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 224 US: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 225 US: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 226 US: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 227 US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 228 US: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 229 US: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 230 US: TOTAL NUMBER OF WOMEN WHO UNDERGO NIPT TESTING, 2023–2030 (MILLION UNITS)
  • TABLE 231 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 232 CANADA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 233 CANADA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 234 CANADA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 235 CANADA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 236 CANADA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 237 CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 238 CANADA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 239 CANADA: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 240 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 241 EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 242 EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 243 EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 244 EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 245 EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 246 EUROPE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 247 EUROPE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 248 EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 249 EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 250 EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 251 GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 252 GERMANY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 253 GERMANY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 254 GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 255 GERMANY: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 256 GERMANY: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 257 GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 258 GERMANY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 259 GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 260 UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 261 UK: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 262 UK: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 263 UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 264 UK: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 265 UK: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 266 UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 267 UK: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 268 UK: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 269 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 270 FRANCE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 271 FRANCE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 272 FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 273 FRANCE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 274 FRANCE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 275 FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 276 FRANCE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 277 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 278 ITALY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 279 ITALY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 280 ITALY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 281 ITALY: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 282 ITALY: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 283 ITALY: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 284 ITALY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 285 ITALY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 286 ITALY: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 287 SPAIN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 288 SPAIN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 289 SPAIN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 290 SPAIN: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 291 SPAIN: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 292 SPAIN: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 293 SPAIN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 294 SPAIN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 295 SPAIN: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 296 REST OF EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 297 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 298 REST OF EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 299 REST OF EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 300 REST OF EUROPE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 301 REST OF EUROPE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 302 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 303 REST OF EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 304 REST OF EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 305 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 306 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 307 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 308 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 309 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 310 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 311 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 312 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 313 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 314 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 315 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 316 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 317 CHINA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 318 CHINA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 319 CHINA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 320 CHINA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 321 CHINA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 322 CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 323 CHINA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 324 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 325 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 326 JAPAN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 327 JAPAN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 328 JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 329 JAPAN: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 330 JAPAN: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 331 JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 332 JAPAN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 333 JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 334 INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 335 INDIA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 336 INDIA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 337 INDIA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 338 INDIA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 339 INDIA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 340 INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 341 INDIA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 342 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 343 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 344 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 345 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 346 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 347 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 348 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 349 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 350 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 351 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 352 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 353 LATIN AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 354 LATIN AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 355 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 356 LATIN AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 357 LATIN AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 358 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 359 LATIN AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 360 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 361 LATIN AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 362 LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 363 BRAZIL: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 364 BRAZIL: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 365 BRAZIL: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 366 BRAZIL: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 367 BRAZIL: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 368 BRAZIL: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 369 BRAZIL: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 370 BRAZIL: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 371 BRAZIL: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 372 MEXICO: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 373 MEXICO: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 374 MEXICO: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 375 MEXICO: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 376 MEXICO: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 377 MEXICO: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 378 MEXICO: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 379 MEXICO: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 380 MEXICO: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 381 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 382 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 383 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 384 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 385 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 386 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 387 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 388 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 389 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 390 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 391 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
  • TABLE 392 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION)
  • TABLE 393 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 394 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 395 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 396 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 397 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 398 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
  • TABLE 399 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 400 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN LIQUID BIOPSY MARKET, JANUARY 2021−JUNE 2025
  • TABLE 401 LIQUID BIOPSY MARKET: DEGREE OF COMPETITION
  • TABLE 402 LIQUID BIOPSY MARKET: REGION FOOTPRINT
  • TABLE 403 LIQUID BIOPSY MARKET: PRODUCT & SERVICE FOOTPRINT
  • TABLE 404 LIQUID BIOPSY MARKET: APPLICATION FOOTPRINT
  • TABLE 405 LIQUID BIOPSY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 406 LIQUID BIOPSY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY PRODUCT & SERVICE
  • TABLE 407 LIQUID BIOPSY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY REGION
  • TABLE 408 LIQUID BIOPSY MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025
  • TABLE 409 LIQUID BIOPSY MARKET: DEALS, JANUARY 2021–JUNE 2025
  • TABLE 410 LIQUID BIOPSY MARKET: EXPANSIONS, JANUARY 2021–JUNE 2025
  • TABLE 411 NATERA, INC.: COMPANY OVERVIEW
  • TABLE 412 NATERA, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 413 NATERA, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–JUNE 2025
  • TABLE 414 NATERA, INC.: DEALS, JANUARY 2021−JUNE 2025
  • TABLE 415 NATERA, INC.: OTHER DEVELOPMENTS, JANUARY 2021– JUNE 2025
  • TABLE 416 GUARDANT HEALTH: COMPANY OVERVIEW
  • TABLE 417 GUARDANT HEALTH: PRODUCTS/SERVICES OFFERED
  • TABLE 418 GUARDANT HEALTH: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−JUNE 2025
  • TABLE 419 GUARDANT HEALTH: DEALS, JANUARY 2021−JUNE 2025
  • TABLE 420 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
  • TABLE 421 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 422 MYRIAD GENETICS, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025
  • TABLE 423 MYRIAD GENETICS, INC.: DEALS, JANUARY 2021−JUNE 2025
  • TABLE 424 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 425 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 426 ILLUMINA, INC.:PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−JUNE 2025
  • TABLE 427 ILLUMINA, INC.: DEALS, JANUARY 2021−JUNE 2025
  • TABLE 428 ILLUMINA, INC.: EXPANSIONS, JANUARY 2021−JUNE 2025
  • TABLE 429 ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2021−JUNE 2025
  • TABLE 430 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 431 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 432 F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025
  • TABLE 433 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2021−JUNE 2025
  • TABLE 434 QIAGEN N.V.: COMPANY OVERVIEW
  • TABLE 435 QIAGEN N.V.: PRODUCTS/SERVICES OFFERED
  • TABLE 436 QIAGEN N.V.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025
  • TABLE 437 QIAGEN N.V.: DEALS, JANUARY 2021−JUNE 2025
  • TABLE 438 QIAGEN: EXPANSIONS, JANUARY 2021−JUNE 2025
  • TABLE 439 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW
  • TABLE 440 EXACT SCIENCES CORPORATION: PRODUCTS/SERVICES OFFERED
  • TABLE 441 EXACT SCIENCES CORPORATION: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025
  • TABLE 442 EXACT SCIENCES CORPORATION: DEALS, JANUARY 2021−JUNE 2025
  • TABLE 443 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 444 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 445 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025
  • TABLE 446 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021−JUNE 2025
  • TABLE 447 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021−JUNE 2025
  • TABLE 448 GRAIL, INC.: COMPANY OVERVIEW
  • TABLE 449 GRAIL, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 450 GRAIL, INC.: PRODUCT/SERVICE APPROVALS, JANUARY 2021−JUNE 2025
  • TABLE 451 GRAIL, INC.: DEALS, JANUARY 2021−JUNE 2025
  • TABLE 452 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 453 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 454 BIO-RAD LABORATORIES, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025
  • TABLE 455 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021−JUNE 2025
  • TABLE 456 SYSMEX CORPORATION: COMPANY OVERVIEW
  • TABLE 457 SYSMEX CORPORATION: PRODUCTS/SERVICES OFFERED
  • TABLE 458 SYSMEX CORPORATION: DEALS, JANUARY 2021−JUNE 2025
  • TABLE 459 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2021−JUNE 2025
  • TABLE 460 MDXHEALTH: COMPANY OVERVIEW
  • TABLE 461 MDXHEALTH: PRODUCTS/SERVICES OFFERED
  • TABLE 462 MDXHEALTH: DEALS, JANUARY 2021−JUNE 2025
  • TABLE 463 PERSONALIS, INC.: COMPANY OVERVIEW
  • TABLE 464 PERSONALIS, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 465 PERSONALIS, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025
  • TABLE 466 PERSONALIS, INC.: DEALS, JANUARY 2021−JUNE 2025
  • TABLE 467 THE MENARINI GROUP: COMPANY OVERVIEW
  • TABLE 468 THE MENARINI GROUP: PRODUCTS/SERVICES OFFERED
  • TABLE 469 THE MENARINI GROUP: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025
  • TABLE 470 THE MENARINI GROUP: DEALS, JANUARY 2021−JUNE 2025
  • TABLE 471 NEOGENOMICS LABORATORIES: COMPANY OVERVIEW
  • TABLE 472 ANGLE PLC: COMPANY OVERVIEW
  • TABLE 473 LABCORP HOLDINGS INC.: COMPANY OVERVIEW
  • TABLE 474 BIO-TECHNE: COMPANY OVERVIEW
  • TABLE 475 MESA LABS, INC.: COMPANY OVERVIEW
  • TABLE 476 MEDGENOME: COMPANY OVERVIEW
  • TABLE 477 LUNGLIFE AI, INC.: COMPANY OVERVIEW
  • TABLE 478 STRAND: COMPANY OVERVIEW
  • TABLE 479 VORTEX BIOTECH HOLDINGS: COMPANY OVERVIEW
  • TABLE 480 FREENOME HOLDINGS, INC.: COMPANY OVERVIEW
  • TABLE 481 LUCENCE HEALTH INC.: COMPANY OVERVIEW
  • TABLE 482 NEW DAY DIAGNOSTICS, LLC: COMPANY OVERVIEW


★調査レポート[リキッドバイオプシーの世界市場（～2030年）] (コード：MD 4456)販売に関する免責事項を必ずご確認ください。
★調査レポート[リキッドバイオプシーの世界市場（～2030年）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • バスバーの世界市場（～2030年）
  • 世界の温度制御半導体チラー市場（～2030年）
  • ビデオ管理システム（VMS）の世界市場（～2030年）
  • 空カプセルの世界市場（～2030年）
  • 世界の製造業における人工知能(AI)市場（～2030年）
  • 脳磁図の世界市場2023年-2030年
  • ギアモーターの世界市場予測（～2030年）
  • アデノ随伴ウイルスベクター製造の世界市場-2023年～2030年
  • 滅菌済み即使用バイアルの世界市場（～2030年）
  • エクソソーム研究市場～2030年までの世界予測

    • ◆H&Iグローバルリサーチのお客様（例）◆